AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18937123 — intervention group
Group type: EXPERIMENTAL
Intervention: Female partner with experience of extradyadic sexual activity (ESA)
Number of subjects: 399
Study 18937123 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partner of a woman with experience of ESA
Number of subjects: 399
Study 18937123 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude of male partner
Number of subjects: 399
Study 16395998 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 16395998 — intervention group
Group type: COMPARATOR
Intervention: Reference treatment
Number of subjects: 0
Study 12211216 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 4 mg
Number of subjects: 25
Study 12211216 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 8 mg
Number of subjects: 25
Study 12211216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12211216 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (4 mg and 8 mg)
Number of subjects: 25
Study 10599957 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrates (PC) transfused immediately after cardiopulmonary bypass
Number of subjects: 35
Study 10599957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PC)
Number of subjects: 35
Study 10599957 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrates (PC)
Number of subjects: 35
Study 10599957 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrates (PC) stored for 1 day
Number of subjects: 35
Study 8831364 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.15 mg/kg)
Number of subjects: 34
Study 8831364 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg)
Number of subjects: 34
Study 8831364 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (15 mg/kg)
Number of subjects: 34
Study 8831364 — intervention group
Group type: COMPARATOR
Intervention: Control state (no intervention)
Number of subjects: 34
Study 2008800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with a highly purified, inactivated virus particle vaccine
Number of subjects: 0
Study 2008800 — intervention group
Group type: COMPARATOR
Intervention: Naturally acquired tick‐borne encephalitis (TBE)
Number of subjects: 0
Study 7117279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholescintigraphy
Number of subjects: 77
Study 31535498 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Active Mobilization (EAM)
Number of subjects: 50
Study 31535498 — intervention group
Group type: COMPARATOR
Intervention: Immobilization
Number of subjects: 50
Study 28930058 — intervention group
Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO intervention
Number of subjects: 221
Study 28930058 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 221
Study 26088378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 10 mg or 15 mg
Number of subjects: 370
Study 26088378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 24759957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment plus a theory‐based behaviour change intervention led by a facilitator
Number of subjects: 478
Study 24759957 — intervention group
Group type: COMPARATOR
Intervention: Intensive treatment
Number of subjects: 478
Study 22689805 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m² per day as a 1-hour intravenous infusion for five consecutive days every 4 weeks
Number of subjects: 485
Study 22689805 — intervention group
Group type: COMPARATOR
Intervention: Treatment choice (TC) - supportive care or cytarabine 20 mg/m² per day as a subcutaneous injection for 10 consecutive days every 4 weeks
Number of subjects: 485
Study 22689805 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 485
Study 22689805 — intervention group
Group type: COMPARATOR
Intervention: Treatment choice (TC)
Number of subjects: 485
Study 19424073 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1.2 g oral, single dose 1 hour before surgery)
Number of subjects: 60
Study 19424073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19424073 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 60
Study 16697113 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy regimen including active exercises (10 appointments within 14 days)
Number of subjects: 200
Study 16697113 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (immobilization with a soft collar for 7 days)
Number of subjects: 200
Study 15265256 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) 300 mg plus fixed-dose lamivudine 150 mg/zidovudine 300 mg (COM) twice daily
Number of subjects: 329
Study 15265256 — intervention group
Group type: COMPARATOR
Intervention: Indinavir (IDV) plus COM twice daily
Number of subjects: 329
Study 11413106 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM26226
Number of subjects: 0
Study 11413106 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 9160758 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR (180 mg)
Number of subjects: 272
Study 9160758 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (1 mg)
Number of subjects: 272
Study 9160758 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR + Trandolapril (fixed combination)
Number of subjects: 272
Study 9160758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 7961013 — intervention group
Group type: EXPERIMENTAL
Intervention: Multileaf collimator combined with three-dimensional treatment planning
Number of subjects: 245
Study 7961013 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal neutron beam delivery techniques
Number of subjects: 245
Study 7961013 — intervention group
Group type: COMPARATOR
Intervention: Control treatment with photons
Number of subjects: 245
Study 3230458 — intervention group
Group type: EXPERIMENTAL
Intervention: HRA with feedback
Number of subjects: 350
Study 3230458 — intervention group
Group type: EXPERIMENTAL
Intervention: HRA without feedback
Number of subjects: 350
Study 31735430 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with prior preeclampsia
Number of subjects: 275930
Study 31735430 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 275930
Study 31735430 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with preeclampsia requiring preterm delivery
Number of subjects: 275930
Study 31735430 — intervention group
Group type: COMPARATOR
Intervention: Women without prior preeclampsia
Number of subjects: 275930
Study 29721715 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional treatment (LRT)
Number of subjects: 21200
Study 29721715 — intervention group
Group type: COMPARATOR
Intervention: No locoregional treatment (no-LRT)
Number of subjects: 21200
Study 29721715 — intervention group
Group type: EXPERIMENTAL
Intervention: LRT (group 1, 0-7 points)
Number of subjects: 21200
Study 29721715 — intervention group
Group type: EXPERIMENTAL
Intervention: LRT (group 2, 7-17 points)
Number of subjects: 21200
Study 29721715 — intervention group
Group type: EXPERIMENTAL
Intervention: LRT (training cohort)
Number of subjects: 21200
Study 29721715 — intervention group
Group type: EXPERIMENTAL
Intervention: LRT (internal validation)
Number of subjects: 21200
Study 28186569 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (BDI score ≥14)
Number of subjects: 3086
Study 28186569 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate depression (BDI score ≥20)
Number of subjects: 3086
Study 26437532 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 57
Study 26437532 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline or Chloramphenicol (Control)
Number of subjects: 57
Study 23782624 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 275
Study 23782624 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 275
Study 20497261 — intervention group
Group type: EXPERIMENTAL
Intervention: David's classification (DC)
Number of subjects: 120
Study 20497261 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted method (CASA SC)
Number of subjects: 120
Study 18499556 — intervention group
Group type: COMPARATOR
Intervention: Iscador therapy (mistletoe preparation)
Number of subjects: 284
Study 14691193 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Automated Perimetry (CAP) with mental workload (PASAT)
Number of subjects: 10
Study 14691193 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminance Size Threshold Perimetry (LSTP) with mental workload (PASAT)
Number of subjects: 10
Study 14691193 — intervention group
Group type: COMPARATOR
Intervention: Paced Auditory Serial Addition Test (PASAT)
Number of subjects: 10
Study 11605151 — intervention group
Group type: EXPERIMENTAL
Intervention: Low compliance dilation device (LCDD, polyethylene balloon, Rigiflex, Microvasive Boston Scientific, USA, n = 18)
Number of subjects: 35
Study 11605151 — intervention group
Group type: COMPARATOR
Intervention: High compliance dilation device (HCDD, latex balloon, Rüsch Inc., Germany, n = 17)
Number of subjects: 35
Study 11605151 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LCDD and HCDD)
Number of subjects: 35
Study 9717015 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sotalol (selective approach)
Number of subjects: 214
Study 9717015 — intervention group
Group type: COMPARATOR
Intervention: Non-selective approach (all patients treated)
Number of subjects: 214
Study 9717015 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective approach
Number of subjects: 214
Study 7981992 — intervention group
Group type: EXPERIMENTAL
Intervention: SASP + MTX
Number of subjects: 40
Study 7981992 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 40
Study 2921096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg Ro 16-6028
Number of subjects: 10
Study 2921096 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 10
Study 2921096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2921096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg Ro 16-6028
Number of subjects: 10
Study 2921096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg Ro 16-6028
Number of subjects: 10
Study 1168170 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, attenuated recombinant influenza vaccine (Alice strain) administered intranasally
Number of subjects: 0
Study 1168170 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous, inactivated, bivalent influenza vaccine
Number of subjects: 0
Study 1168170 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 0
Study 31677046 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly lifestyle education program including advice on nutritional changes and physical activity enhancement.
Number of subjects: 0
Study 31677046 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group receiving monthly lectures on non-cardiovascular topics with verbal advice on healthy diet and exercise.
Number of subjects: 0
Study 31256021 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 658
Study 28287021 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching intervention for 6 months
Number of subjects: 22
Study 28287021 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching intervention for 3 months
Number of subjects: 22
Study 28287021 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining after 6 months
Number of subjects: 22
Study 25982601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide, three times daily for three weeks
Number of subjects: 69
Study 25982601 — intervention group
Group type: COMPARATOR
Intervention: Placebo, three times daily for three weeks
Number of subjects: 69
Study 23952999 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine (15 mg/day for 50% of patients, 10 mg/day for 28%)
Number of subjects: 1226
Study 23952999 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 1226
Study 20948195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic (IT) methylprednisolone injection
Number of subjects: 65
Study 20948195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear drops of methylprednisolone
Number of subjects: 65
Study 20948195 — intervention group
Group type: COMPARATOR
Intervention: Blank control (no treatment)
Number of subjects: 65
Study 19637947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosamprenavir 1400 mg once/day
Number of subjects: 21
Study 19637947 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg once/day
Number of subjects: 21
Study 19637947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosamprenavir 1400 mg plus Atazanavir 400 mg once/day
Number of subjects: 21
Study 16293317 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (45/6.4 mg/kg/day in two divided doses for 10 days)
Number of subjects: 180
Study 15156472 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea, 2.5 mL 3 times per day for 7 days before and 7 days after inoculation
Number of subjects: 48
Study 15156472 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 2.5 mL 3 times per day for 7 days before and 7 days after inoculation
Number of subjects: 48
Study 15156472 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea
Number of subjects: 48
Study 15156472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11288041 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.4 g/kg body weight)
Number of subjects: 8
Study 11288041 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8
Study 9594206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan (CU) membrane
Number of subjects: 22
Study 9594206 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) membrane
Number of subjects: 22
Study 9594206 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulphone (PS) membrane
Number of subjects: 22
Study 8323333 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous human recombinant erythropoietin (r‐HuEpo)
Number of subjects: 11
Study 3090274 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 91
Study 3090274 — intervention group
Group type: COMPARATOR
Intervention: Combination of pethidine and hyoscine butyl bromide
Number of subjects: 91
Study 29523267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM)
Number of subjects: 0
Study 29523267 — intervention group
Group type: COMPARATOR
Intervention: Clinic blood pressure (CBP) readings
Number of subjects: 0
Study 27584019 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein low fat diet (35% protein, 40% carbohydrate, 25% fat; n = 57)
Number of subjects: 118
Study 27584019 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher carbohydrate low fat diet (17% protein, 58% carbohydrate, 25% fat; n = 61)
Number of subjects: 118
Study 27584019 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 118
Study 25033346 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue grafts (SCTG)
Number of subjects: 13
Study 25033346 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) allografts
Number of subjects: 13
Study 25033346 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SCTG and ADM)
Number of subjects: 13
Study 25033346 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 13
Study 22420717 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 60
Study 22420717 — intervention group
Group type: COMPARATOR
Intervention: LMA ProSeal
Number of subjects: 60
Study 20042440 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentler words for administration of the local anesthetic
Number of subjects: 140
Study 20042440 — intervention group
Group type: COMPARATOR
Intervention: Harsher nocebo words for administration of the local anesthetic
Number of subjects: 140
Study 18378354 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (5‐8 mg/kg)
Number of subjects: 1286
Study 18378354 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin (10‐20 mg/kg)
Number of subjects: 1286
Study 18378354 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (5‐8 mg/kg) in trial 1
Number of subjects: 1286
Study 18378354 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin (10‐20 mg/kg) in trial 1
Number of subjects: 1286
Study 18378354 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (5‐8 mg/kg) in trial 2
Number of subjects: 1286
Study 18378354 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin (10‐20 mg/kg) in trial 2
Number of subjects: 1286
Study 18378354 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (5‐8 mg/kg) for T. tonsurans
Number of subjects: 1286
Study 18378354 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin (10‐20 mg/kg) for M. canis
Number of subjects: 1286
Study 15800520 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT) autograft
Number of subjects: 85
Study 15800520 — intervention group
Group type: COMPARATOR
Intervention: Semitendinosus and gracilis tendon (STG) autograft
Number of subjects: 85
Study 12045062 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-hydrogel balafilcon A (PureVision) worn on a 30-day continuous wear schedule
Number of subjects: 212
Study 12045062 — intervention group
Group type: COMPARATOR
Intervention: Traditional hydrogel (Acuvue) worn on a 7-day extended wear schedule
Number of subjects: 212
Study 12045062 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lens types
Number of subjects: 212
Study 12045062 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-hydrogel balafilcon A (PureVision)
Number of subjects: 212
Study 9549713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic range of motion (DROM) training, performed 5 days a week for 6 weeks, involving active movement into knee extension and holding the position.
Number of subjects: 58
Study 9549713 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretch, performed 5 days a week for 6 weeks, consisting of one 30-second static stretch.
Number of subjects: 58
Study 9549713 — intervention group
Group type: COMPARATOR
Intervention: Control group, no stretching performed.
Number of subjects: 58
Study 7638926 — intervention group
Group type: EXPERIMENTAL
Intervention: Artroflow device
Number of subjects: 95
Study 7638926 — intervention group
Group type: COMPARATOR
Intervention: Control group (Heparin and physical methods)
Number of subjects: 95
Study 2692823 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (2 gm daily)
Number of subjects: 750
Study 2692823 — intervention group
Group type: COMPARATOR
Intervention: Clavulanate‐potentiated amoxicillin (1.125 gm daily)
Number of subjects: 750
Study 778655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 12
Study 778655 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 12
Study 31042621 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS intervention (n = 40)
Number of subjects: 105
Study 31042621 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n = 40)
Number of subjects: 105
Study 31042621 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list, no treatment, n = 25)
Number of subjects: 105
Study 28403269 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM®‐26 (Cohesive Polydensified Matrix®)
Number of subjects: 45
Study 28403269 — intervention group
Group type: COMPARATOR
Intervention: VYC®‐20 (VYCROSS®)
Number of subjects: 45
Study 26063507 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (3 months)
Number of subjects: 58
Study 26063507 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational programme + breathing exercises)
Number of subjects: 58
Study 22964882 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) at a dose of 5 mg on day 1 of each course of low-dose Ara-C (LDAC)
Number of subjects: 495
Study 22964882 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Ara-C (LDAC) alone
Number of subjects: 495
Study 22040189 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) at a target dose of 1.2 mg/kg/day for 8 weeks
Number of subjects: 128
Study 22040189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 19402154 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (75 mg/day for 2 months)
Number of subjects: 34
Study 19402154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16469979 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LFD) (17% of energy from fat)
Number of subjects: 66
Study 16469979 — intervention group
Group type: COMPARATOR
Intervention: Moderate-fat diet (MFD) (34% of energy from fat)
Number of subjects: 66
Study 16469979 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model with trans 18:1, 18:2n-6, and vaccenic acid (18:1n-7)
Number of subjects: 66
Study 15258716 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 10
Study 15258716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17364300 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (148 women)
Number of subjects: 301
Study 17364300 — intervention group
Group type: COMPARATOR
Intervention: Control group (153 women)
Number of subjects: 301
Study 11254229 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% oxygen (oxygen enrichment)
Number of subjects: 24
Study 11254229 — intervention group
Group type: COMPARATOR
Intervention: Ambient air (control)
Number of subjects: 24
Study 8875537 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral formula supplemented with arginine, omega‐3 fatty acids, and nucleotides (A)
Number of subjects: 41
Study 8875537 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard enteral formula (B)
Number of subjects: 41
Study 8875537 — intervention group
Group type: COMPARATOR
Intervention: Low calorie/low fat intravenous solution (C)
Number of subjects: 41